Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target

por Sabanathan, Dhanusha, Lund, Maria E., Campbell, Douglas H., Walsh, Bradley J., Gurney, Howard
Publicado 2021

Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment

por Zhang, Wei, Campbell, Douglas H., Walsh, Bradley J., Packer, Nicolle H., Liu, Dingbin, Wang, Yuling
Publicado 2022

Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization

por Truong, Quach, Justiniano, Irene O., Nocon, Aline L., Soon, Julie T., Wissmueller, Sandra, Campbell, Douglas H., Walsh, Bradley J.
Publicado 2016

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

por Lund, Maria E., Howard, Christopher B., Thurecht, Kristofer J., Campbell, Douglas H., Mahler, Stephen M., Walsh, Bradley J.
Publicado 2020

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer

por Campbell, Douglas H., Lund, Maria E., Nocon, Aline L., Cozzi, Paul J., Frydenberg, Mark, De Souza, Paul, Schiller, Belinda, Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Walsh, Bradley J.
Publicado 2018

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab(®)-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery

por Polikarpov, Dmitry M., Campbell, Douglas H., McRobb, Lucinda S., Wu, Jiehua, Lund, Maria E., Lu, Yanling, Deyev, Sergey M., Davidson, Andrew S., Walsh, Bradley J., Zvyagin, Andrei V., Gillatt, David A.
Publicado 2020

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis

por Sayyadi, Nima, Justiniano, Irene, Wang, Yan, Zheng, Xianlin, Zhang, Wei, Jiang, Lianmei, Polikarpov, Dmitry M., Willows, Robert D., Gillatt, David, Campbell, Douglas, Walsh, Bradley J., Yuan, Jingli, Lu, Yiqing, Packer, Nicolle H., Wang, Yuling, Piper, James A.
Publicado 2022

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker

por Levin, Rachel A., Lund, Maria E., Truong, Quach, Wu, Angela, Shore, Neal D., Saltzstein, Daniel R., Concepcion, Raoul S., Paivanas, Thomas A., van Breda, Arletta, Beebe-Dimmer, Jennifer, Ruterbusch, Julie J., Wissmueller, Sandra, Campbell, Douglas H., Walsh, Bradley J.
Publicado 2018

Targeted beta therapy of prostate cancer with (177)Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

por Yeh, Mei-Chun, Tse, Brian W. C., Fletcher, Nicholas L., Houston, Zachary H., Lund, Maria, Volpert, Marianna, Stewart, Chelsea, Sokolowski, Kamil A., Jeet, Varinder, Thurecht, Kristofer J., Campbell, Douglas H., Walsh, Bradley J., Nelson, Colleen C., Russell, Pamela J.
Publicado 2020